Lobbying Information
Subject Matters
- Government Procurement
- Health
- Industry
- Intellectual Property
- International Trade
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution, Policies or Program
- The Bill formerly known as Bill C-393 (Canada Access to Medicines Regime) with respect to simplifying the process for pharmaceutical manufacturers to participate including sections on requirements, process, outcomes and responsibilities.
Legislative Proposal, Bill or Resolution, Regulation
- Patent Act - lobby for changes on all rules and processes for the listing of generic pharmaceutical products.
Policies or Program, Regulation
- Trade Agreements (NAFTA) North American Free Trade Agreement, WTO (World Trade Organization), European-Canada Free Trade Agreement policies, regulations,patents: with respect to terms, dispute settlements; pharmaceutical products policies, reviews/changes/updates; and all other changes that impact the ability to introduce products or export to other countries.
Regulation
- Health Canada generic submissions review/approvals: with respect to the submission of new generic products to Health Canada and the resources, timing, structures and requirements needed to complete process.
- Notice of compliance regulations (NOC): with respect to application of regulations, reviews/changes as it relates to the approval of generic drugs in Canada.
Communication Techniques
-
Written communication
-
Grass-roots communication
Government Institutions
-
Canadian Heritage (PCH)
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Industry Canada
-
Justice Canada (JC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Revenue Canada (RC)
-
Solicitor General Canada (SGC)
-
Treasury Board Of Canada Secretariat (TBS)
Government institutions added through a monthly communication report
In-house Corporation Details
Description of activities
Apotex is a Canadian-owned pharmaceutical company which researches, develops, manufactures and distributes 300 medicines to the healthcare system and exports these to 115 countries. Apotex's 2006 Research and Development (R&D) budget was $179 million - positioning it in the top 15 companies for all industrial sectors (20% of sales).
Responsible officer name and position during the period of this registration
JACK KAY,
PRESIDENT & COO
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
150 Signet Drive
Toronto, ON M9L 1T9
Canada
Telephone number:
416-749-9300
Ext.
7366
Fax number:
416-401-3835
Parent Company Information
Apotex Inc. is not a subsidiary of any other parent companies.
Subsidiary Beneficiary Information
- ACCUCAPS INDUSTRIES LIMITED
-
2125 AMBASSADOR DRIVE
WINDSOR, ON N9C 3R5
Canada
- APOPHARMA INC.
-
200 BARMAC DRIVE
TORONTO, ON M9L 2Z7
Canada
- APOTEX FERMENTATION INC.
-
50 SCURFIELD BOULEVARD
WINNIPEG, MB R3Y 1G4
Canada
- APOTEX INTERNATIONAL INC.
-
200 BARMAC DRIVE
TORONTO, ON M9L 2Z7
Canada
- APOTEX PHARMACHEM INC.
-
34 SPALDING DRIVE
BRANTFORD, ON N9C 3R5
Canada
- STARPLEX SCIENTIFIC
-
50 STEINWAY BOULEVARD
ETOBICOKE, ON M8W 6Y3
Canada
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Bruce Clark,
VP Regulatory & Medical Affairs |
No public offices held
- Jeremy Desai,
EVP Global R&D Quality |
No public offices held
- Peter Hardwick,
Vice President, Marketing |
No public offices held
- JACK KAY,
PRESIDENT & COO |
No public offices held
- BARRY SHERMAN,
CHAIRMAN & Chief Executive Officer (CEO) |
No public offices held
- Shashank Upadhye,
VP Global Intellectual Properties |
No public offices held
- Jeff Watson,
Chief Commercial Officer |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Elie Betito,
Director, Public and Government Affairs |
No public offices held
